| Alvin Wessel Jr, | |
|
1200 Highland Park Dr, Rapid City, SD 57701-5335 | |
| (605) 341-7244 | |
| Not Available |
| Full Name | Alvin Wessel Jr |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 1200 Highland Park Dr, Rapid City, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043247406 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 1571 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Alvin Wessel Jr, 1200 Highland Park Dr, Rapid City, SD 57701-5335 Ph: () - | Alvin Wessel Jr, 1200 Highland Park Dr, Rapid City, SD 57701-5335 Ph: (605) 341-7244 |
News Archive
Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.
Opening new doors for biomedical and neuroscience research, Elizabeth Hillman, associate professor of biomedical engineering at Columbia Engineering and of radiology at Columbia University Medical Center, has developed a new microscope that can image living things in 3D at very high speeds.
Swedes eat on average twice as much meat, and considerably more fruit and vegetables in the early 21st century than in the 1870s. Nevertheless, the surface area required to produce our food has decreased, measured per person. But this decrease is largely based on non-sustainable use of resources.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.
› Verified 3 days ago
Kimberly Kennedy, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 E Minnesota St, Suite 210, Rapid City, SD 57701 Phone: 605-342-3280 Fax: 605-721-8412 | |
Wayne Plooster, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 717 Saint Francis St, Rapid City, SD 57701 Phone: 605-342-2880 | |
Gordon Abernathie, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5410 Sheridan Lake Rd, Rapid City, SD 57702 Phone: 605-348-4141 Fax: 605-342-7880 | |
Dr. Kay Kelts, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 717 Saint Francis St, Rapid City, SD 57701 Phone: 605-342-2880 | |
Samuel W Huot, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3810 Jackson Blvd, Rapid City, SD 57702 Phone: 605-343-4050 | |
Taylor Kapsch, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2822 Jackson Blvd Ste 101, Rapid City, SD 57702 Phone: 605-341-1208 |